AbbVie Inc. CDR (4AB0)

Profile

https://www.abbvie.com

AbbVie Inc. CDR is a Canadian Depositary Receipt that provides Canadian investors with exposure to AbbVie Inc., a research-based biopharmaceutical company, trading in Canadian dollars with a currency hedge to minimize foreign exchange risk. AbbVie Inc. engages in the discovery, development, manufacturing, and sale of pharmaceutical products worldwide, with a strong focus on immunology through key therapies like Humira, Skyrizi, and Rinvoq; oncology with Imbruvica and Venclexta; neuroscience; aesthetics including Botox; eye care products such as Ozurdex and Restasis; and treatments for virology, hepatitis C, HIV, and gastrointestinal conditions like Creon and Linzess. The company addresses chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, as well as neurological disorders and blood cancers. Founded in 2013 and headquartered in North Chicago, Illinois, AbbVie Inc. CDR enables accessible participation in the global biopharmaceutical sector for Canadian markets.